Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variant allele frequency: a decision-making tool in precision oncology?
Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, Criscitiello C, Marra A, Subbiah V, Curigliano G. Boscolo Bielo L, et al. Among authors: curigliano g. Trends Cancer. 2023 Dec;9(12):1058-1068. doi: 10.1016/j.trecan.2023.08.011. Epub 2023 Sep 12. Trends Cancer. 2023. PMID: 37704501 Review.
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.
Kiesewetter B, Dafni U, de Vries EGE, Barriuso J, Curigliano G, González-Calle V, Galotti M, Gyawali B, Huntly BJP, Jäger U, Latino NJ, Malcovati L, Oosting SF, Ossenkoppele G, Piccart M, Raderer M, Scarfò L, Trapani D, Zielinski CC, Wester R, Zygoura P, Macintyre E, Cherny NI; ESMO-MCBS Working Group and Extended Working Group. Kiesewetter B, et al. Among authors: curigliano g. Ann Oncol. 2023 Sep;34(9):734-771. doi: 10.1016/j.annonc.2023.06.002. Epub 2023 Jun 19. Ann Oncol. 2023. PMID: 37343663
The immunogram of inflammatory breast cancer.
Valenza C, Trapani D, Fusco N, Wang X, Cristofanilli M, Ueno NT, Curigliano G. Valenza C, et al. Among authors: curigliano g. Cancer Treat Rev. 2023 Sep;119:102598. doi: 10.1016/j.ctrv.2023.102598. Epub 2023 Jul 8. Cancer Treat Rev. 2023. PMID: 37437342 Review.
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
Valenza C, Trapani D, Gandini S, Sposetti C, Boscolo Bielo L, Marra A, Giarratano T, Favero D, Cortesi L, Moscetti L, Pistelli M, Berardi R, Zambelli A, Lambertini M, Del Mastro L, Guarneri V, Vernieri C, Curigliano G. Valenza C, et al. Among authors: curigliano g. Eur J Cancer. 2023 Sep;190:112944. doi: 10.1016/j.ejca.2023.112944. Epub 2023 Jun 20. Eur J Cancer. 2023. PMID: 37437366
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.
Cobanaj M, Corti C, Dee EC, McCullum L, Boldrini L, Schlam I, Tolaney SM, Celi LA, Curigliano G, Criscitiello C. Cobanaj M, et al. Among authors: curigliano g. Eur J Cancer. 2024 Feb;198:113504. doi: 10.1016/j.ejca.2023.113504. Epub 2023 Dec 19. Eur J Cancer. 2024. PMID: 38141549 Free article. Review.
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, De Miguel Perez D, Del Re M, Russo A, Curigliano G, Rolfo C, Subbiah V. Gouda MA, et al. Among authors: curigliano g. Ann Oncol. 2024 Mar;35(3):267-275. doi: 10.1016/j.annonc.2023.12.007. Epub 2023 Dec 23. Ann Oncol. 2024. PMID: 38145866 Review.
757 results